PCV13不同基础免疫与加强程序后儿童抗荚膜抗体数量与功能比较
该研究利用既往中耳炎疫苗效果研究留存血清,比较2剂或3剂基础免疫及15月龄加强前后IgG与OPA抗体。2p在ELISA上抗体较低但OPA多数型别无差异,仅6A、6B、5、23F在加强前有差异。2p+1与3p+1对多数血清型保护相似,而2p+0或3p+0可能导致许多儿童第二年抗体不达保护水平。
要点
- 2p与3p基础免疫后OPA保护阈值达标率多数血清型无差异,仅23F例外。
- 15月龄加强后抗体显著升高,支持2p+1或3p+1程序。
- 2p+0或3p+0程序可能使许多儿童第二年失去保护性抗体水平。
核心结论
- 2p+1与3p+1对多数血清型提供相似保护,而2p+0或3p+0可能导致许多儿童第二年抗体不达保护水平。
研究设计与样本
- 利用既往PCV对急性中耳炎效果研究的留存血清,检测2p、3p、15月龄加强前和18月龄加强后四个时间点。
- 共检测169名儿童的390份血清,每个时间点约100份。
主要发现
- 2p在ELISA上抗体水平较低,但OPA仅在6A、6B、5和23F加强前有差异。
- 15月龄加强后抗体显著升高。
- 2p与3p的OPA保护阈值达标率除23F外无差异。
关键数值与推荐
- 以ELISA几何平均浓度和OPA保护阈值达标百分比为评价指标。
临床怎么用
- 在PCV13程序中优先采用2p+1或3p+1,避免2p+0或3p+0以维持第二年保护性抗体。
局限性
- 血清来自既往中耳炎疫苗效果研究的便利留存样本,非随机分组比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Different schedules for pediatric use of the 13-valent pneumococcal conjugate vaccine (PCV-13) are recommended in different countries and the U.S. Advisory Committee on Immunization Practices (ACIP) has considered potential of changing from 3 primary doses plus a booster (3p + 1) to two primary doses plus a booster (2p + 1) for protection against Streptococcus pneumoniae. In this paper, we report results of IgG antibody measured by ELISA and opsonophagocytic assay (OPA) after 2p, 3p, at child age 15 months of pre-booster and 18 months (post-booster) in serum samples opportunistically available from a prior study that focused on PCV effectiveness against AOM. A total of ~ 100 sera for each of the 4 study time points (390 sera tested) from 169 children were tested. Geometric mean concentrations (GMCs) and percentage of children exceeding the presumed protective antibody thresholds measured by ELISA and OPA were calculated. 2p doses produced lower antibody levels measured by ELISA but not OPA until the booster dose for serotypes 6A, 6B, 5 and 23F only. Booster dosing at 15 months resulted in significant increases in antibody. There was no difference in the percentage of children with ≥ correlate of protection (COP) for OPA for 2p vs 3p doses except for serotype 23F. A 2p + 0 or 3p + 0 schedule would likely result in many children failing to sustain protective levels of antibody into the second year of life. We conclude that protection from invasive pneumococcal infection in early childhood would be similar for most serotypes in PCV13 using a 2p + 1 or 3p + 1 but not a 2p + 0 or 3p + 0 schedule.
引用
- Kaur R, Pichichero M. Comparison of anti-capsular antibody quantity and functionality in children after different primary dose and booster schedules of 13 valent-pneumococcal conjugate vaccine. Vaccine. 2020. PMID: 32402752. doi:10.1016/j.vaccine.2020.04.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。